Alimera Sciences
6120 Windward Parkway
Suite 290
Alpharetta
Georgia
30005
United States
Tel: 678-990-5740
Fax: 678-990-5744
Website: http://www.alimerasciences.com/
338 articles about Alimera Sciences
-
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
3/7/2024
Alimera Sciences, Inc. today announced financial results for the fourth quarter and full year 2023.
-
Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update
2/29/2024
Alimera Sciences, Inc. announces that it will report fourth quarter and full year 2023 financial results on March 7, 2024, prior to the market open.
-
Alimera Completes Recruitment for the Synchronicity Study
1/4/2024
Alimera Sciences, Inc. announces that it has completed enrollment for the company’s Synchronicity Study, a prospective, open-label clinical study evaluating the safety and efficacy of YUTIQ in the treatment of chronic non-infectious uveitis and related intraocular inflammation.
-
Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jan 02, 2024
1/2/2024
Alimera Sciences, Inc. announced that Elliot Maltz, C.P.A., has been named Chief Financial Officer effective immediately.
-
Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12/12/2023
Alimera Sciences, Inc. today announced the appointment of Todd Wood as President U.S. effective immediately.
-
Alimera Appoints Maggie A. Pax to Its Board of Directors
11/8/2023
Alimera Sciences, Inc., a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces the addition of Maggie A. Pax to its Board of Directors.
-
Alimera Announces Scientific Data Highlighting ILUVIEN® To Be Presented at the American Academy of Ophthalmology
10/31/2023
Alimera Sciences, Inc. announces that clinical data for ILUVIEN® 0.19 mg taken from the three-year, phase IV, real-world observational PALADIN study evaluating the long-term safety of ILUVIEN for patients with diabetic macular edema, will be featured in three posters and a presentation on behalf of the PALADIN Investigators, during the American Academy of Ophthalmology’s 127th Annual Meeting being held in San Francisco from November 3-6, 2023.
-
Alimera Sciences Reports Third Quarter 2023 Results
10/26/2023
Alimera Sciences, Inc. today announced financial results for the third quarter of 2023. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results.
-
Alimera Sciences to Report Third Quarter 2023 Financial Results on October 26, 2023, and Provide Corporate Update
10/16/2023
Alimera Sciences, Inc. announces that it will report third quarter financial results on October 26, 2023, prior to the market open.
-
Alimera Announces Multiple Presentations Highlighting ILUVIEN® and YUTIQ® Data at Retina Society Annual Congress
10/11/2023
Alimera Sciences, Inc. announces that clinical data for ILUVIEN® 0.19 mg and YUTIQ® 0.18 mg will be featured in five presentations during the Retina Society’s 56th Annual Scientific Meeting being held in New York City from October 11-14, 2023.
-
Alimera Sciences Appoints Jason Werner as Chief Operating Officer
10/3/2023
Alimera Sciences, Inc., a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced the appointment of Jason Werner, Chief Operating Officer, effective October 2, 2023.
-
Alimera Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
9/5/2023
Alimera Sciences Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced today that Rick Eiswirth, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference.
-
Alimera Sciences Reports Second Quarter 2023 Results
8/10/2023
Alimera Sciences, Inc. today announced financial results for the second quarter of 2023.
-
Alimera Sciences to Report Second Quarter 2023 Financial Results on August 10, 2023, and Provide Corporate Update
8/2/2023
Alimera Sciences, Inc. announces that it will report second quarter financial results on August 10, 2023, prior to the market open.
-
Alimera Completes Recruitment for its Landmark NEW DAY Study
5/24/2023
Alimera Sciences, Inc. announces that it has completed enrollment for the company’s NEW DAY clinical trial, a randomized, controlled, multi-center study designed to generate prospective data for ILUVIEN® 0.19 mg as a baseline therapy in patients diagnosed with diabetic macular edema.
-
Alimera Acquires U.S. Commercial Rights to YUTIQ®
5/18/2023
Alimera Sciences, Inc. today announced its acquisition of additional commercialization rights for YUTIQ (fluocinolone acetonide intravitreal insert) 0.18mg for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye from EyePoint Pharmaceuticals, Inc. (EyePoint).
-
Alimera Sciences to Host Rescheduled Corporate Update Call on Thursday, May 18, 2023, at 8:30am ET
5/17/2023
Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera) announces today that it will host its rescheduled corporate update conference call to review first quarter financial results and provide an update on corporate developments on Thursday, May 18, 2023, at 8:30am ET.
-
Alimera Sciences Reports First Quarter 2023 Results
5/15/2023
Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the first quarter of 2023.
-
Alimera Sciences to Report First Quarter 2023 Financial Results on May 15, 2023, and Provide Corporate Update
5/8/2023
Alimera Sciences, Inc. announces that it will report first quarter financial results on May 15, 2023, prior to the market open.
-
Alimera Data to be Featured in Scientific Programming at Upcoming Annual Congress
4/20/2023
Alimera Sciences, Inc. announced that ILUVIEN® will be highlighted in four posters to be presented at the annual Association for Research in Vision and Ophthalmology conference being held in New Orleans, Louisiana from April 23-27, 2023.